The engineered probiotic E. coli Nissle 1917 strain has been reported to enhance the antitumor ability and efficacy of immunotherapies by increasing the concentration of L-arginine in TME and the number of tumor-infiltrating T cells that produce TNF [87, 88]. The gene discussed is TNF; the disease is neoplasm.